Drug Trial Radar · NCT07890350
Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Beijing Keymed Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy
Conditions
- Perennial Allergic Rhinitis (PAR)
Interventions
CM512Biological
Subcutaneous injection, multiple doses. Dosing every 12 weeks (Q12W) or Q24W, according to the protocol. Total treatment duration: 48 weeks.
PlaceboDrug
Subcutaneous injection of matching placebo. multiple doses. Q12W or Q24W according to the protocol. Total treatment duration: 48 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 24Time frame: baseline, Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, CMU
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.